Open Access
| Issue |
BIO Web Conf.
Volume 240, 2026
The 2026 International Conference on Biomedicine, Neuroscience and Biostatistics (ICBNB 2026)
|
|
|---|---|---|
| Article Number | 01029 | |
| Number of page(s) | 7 | |
| Section | Biomedicine, Neuroscience and Biostatistics | |
| DOI | https://doi.org/10.1051/bioconf/202624001029 | |
| Published online | 24 June 2026 | |
- O. Freihat, D. Sipos, A. Kovacs, Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. Front Public Health. 13, 1622954 (2025) [Google Scholar]
- H. Gu, R. Wang, N.M. Beeraka, P. Lu, X. Zhao, L. Li, Y. Liu, D.R. Kandula, R. Fan, T. Gayathri, V.N. Nikolenko, A. Nagalakshmi, B. Basappa, J. Liu, Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries. Chin Med J (Engl). 139, 404–414 (2026) [Google Scholar]
- G. Olatunji, E. Kokori, I. A. Yusuf, O. Akinmoju, T. Isarinade, R. Komolafe, A. Akinoso, A. Akinboade, O. Osaghae, HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence. Heliyon. 9, e17895 (2023) [Google Scholar]
- D.W. Kufe, MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 32, 1073 (2012) [Google Scholar]
- A. Arab, R.Y. Robati, J. Behravan, HER2‑Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development Archivum Immunologiae et Therapiae Experimentalis. 68, 2 (2020) [Google Scholar]
- L. Pan, J. Li, Q. Xu, Z. Gao, M. Yang, X. Wu, X. Li, HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review. Medicine. 103, e38508 (2024) [Google Scholar]
- R. Beroukhim, C.H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Barretina, J.S. Boehm, J. Dobson, M. Urashima, K.T. McHenry, R.M. Pinchback, A.H. Ligon, The landscape of somatic copy-number alteration across human cancers. Nature. 463, 899–905 (2010) [Google Scholar]
- M. Binnewies, E.W. Roberts, K. Kersten, Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24, 541–550 (2018) [Google Scholar]
- K.L. Rock, E. Reits, J. Neefjes, Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 37, 724–737 (2016) [Google Scholar]
- M.A. Morse, E.J. Crosby, J. Force, Clinical trials of self-replicating RNA-based cancer vaccines. Cancer Gene Ther. 30, 803 (2023) [Google Scholar]
- S. Verma, V. Singh, J.E. Lang, S. Gupta, Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics. Cancer Lett. 645, 218350 (2026) [Google Scholar]
- H. Soliman, A. Aldrich, N. Abdo, H. Han, A. Soyano, R. Costa, A. Armaghani, J. Kiluk, N. Khakpour, M.C. Lee, S. Hoover, A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER-breast cancer. NPJ Breast Cancer. 11, 29 (2025) [Google Scholar]
- F. Firuzpour, M. Barancheshmeh, F.F. Ziarani, L. Karami, C. Aram. The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation. Biochem Biophys Rep. 43, 102135 (2025) [Google Scholar]
- E.A. Mittendorf, A. Ardavanis, J. Symanowski, J.L. Murray, N.M. Shumway, J.K. Litton, D.F. Hale, S.A. Perez, E.A. Anastasopoulou, Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 27, 1241 (2016) [Google Scholar]
- A. Elizabeth, L. Biao, M. Michelle, P.H. Julie, B. Igor, M.B. Adrian, S. Grybach, P. Katarina, E.P. George, Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clin Cancer Res. 25, 4248 (2019) [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.